Advantage Alpha Capital Partners LP Decreases Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Advantage Alpha Capital Partners LP decreased its stake in MiMedx Group, Inc. (NASDAQ:MDXG) by 35.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 53,287 shares of the company’s stock after selling 29,596 shares during the period. Advantage Alpha Capital Partners LP’s holdings in MiMedx Group were worth $512,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its holdings in shares of MiMedx Group by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company’s stock worth $16,518,000 after purchasing an additional 44,254 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of MiMedx Group by 6.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock valued at $8,483,000 after buying an additional 92,726 shares during the period. Bank of New York Mellon Corp lifted its position in shares of MiMedx Group by 0.7% during the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock valued at $4,849,000 after buying an additional 3,300 shares during the last quarter. Disciplined Growth Investors Inc. MN grew its stake in shares of MiMedx Group by 0.8% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock worth $2,100,000 after acquiring an additional 2,737 shares during the period. Finally, Wellington Management Group LLP increased its holdings in MiMedx Group by 11.8% in the 3rd quarter. Wellington Management Group LLP now owns 317,274 shares of the company’s stock worth $1,875,000 after acquiring an additional 33,461 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at MiMedx Group

In related news, CAO William Frank Iv Hulse sold 54,596 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now directly owns 440,178 shares in the company, valued at $3,473,004.42. The trade was a 11.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 144,018 shares of company stock valued at $1,130,312. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Price Performance

MiMedx Group stock opened at $8.10 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The firm has a market capitalization of $1.19 billion, a P/E ratio of 14.73 and a beta of 1.97. The business has a fifty day moving average price of $8.36 and a 200-day moving average price of $7.88.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. As a group, equities research analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.